| RTX |
Report |
Adjusted EPS |
BEAT |
pred ~$1.71 vs. cons $1.66 |
MEDIUM |
| RTX |
Report |
Revenue |
BEAT |
pred ~$23.15B vs. cons $22.88B |
MEDIUM |
| RTX |
Report |
Raytheon adjusted operating profit |
BEAT |
pred ~$0.87B vs. cons $0.83B |
MEDIUM |
| RTX |
Guide |
FY2026 adjusted sales midpoint |
BETTER |
guide ~$93.25B vs. cons $93.10B (FY2026) |
MEDIUM |
| RTX |
Guide |
FY2026 adjusted EPS midpoint |
BETTER |
guide ~$6.85 vs. cons $6.83 (FY2026) |
MEDIUM |
| RTX |
Guide |
FY2026 free-cash-flow midpoint |
UNCHANGED |
guide ~$8.50B vs. cons $8.50B (FY2026) |
MEDIUM |
| RTX |
Return |
Day-1 residual (stock − beta × S&P 500) |
+2.8% |
— |
MEDIUM |
| RTX |
Return |
5-day cumulative residual |
+4.2% (FOLLOW-THROUGH) |
A ~$6.85 FY2026 EPS midpoint versus ~$6.83 consensus and ~$93.25B sales midpoint versus ~$93.10B support modest out-period upward revisions; the ~$8.50B FCF midpoint versus ~$8.50B consensus avoids a cash-conversion offset. |
MEDIUM |